An affordable, palatable, maintainable and clinically-useful UC diet, characterized by a low content of sulfur, heme animal-based protein, taurine, animal-saturated fat.

In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16% by weight; caprylyl glycol 0.45-3% by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1% by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13% by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that have a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16% by weight; caprylyl glycol 0.45-3% by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1% by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13% by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that have a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

A method of reducing symptoms of neurodegenerative disease in a human is provided. The method comprises applying to the human a solution or salve to at least one of the skin, the mouth, the nasal cavities, the lungs, the eyes, or the vagina of the human. The applied solution or salve comprises an effective amount of an isomerized or conjugated linoleic acid cation salt having a conjugated diene for at least a measurable improvement in the movement or mental acuity of the human and a structure of -C=C-C=C-. The measurable improvement in the movement or mental acuity of the human is within 4-6 weeks of the applying of the solution or salve. A method of making the conjugated diene and a device for measuring the reduction of systems is also provided.

Ketone bodies can be used to treat the human body from viral infections, and will overcome the cytokine storm, which leads to acute lung injury/acute respiratory distress syndrome. Based on this discovery, methods of treating humans from a viral infection like Covid-19 are disclosed which includes a therapeutically effective amount of an exogenous ketones including, but not limited to, ketone monoester (R)-3-hydroxybutyl (R)-3-hydroxybutanoate.

Ketone bodies can be used to treat the human body from viral infections, and will overcome the cytokine storm, which leads to acute lung injury/acute respiratory distress syndrome. Based on this discovery, methods of treating humans from a viral infection like Covid-19 are disclosed which includes a therapeutically effective amount of an exogenous ketones including, but not limited to, ketone monoester (R)-3-hydroxybutyl (R)-3-hydroxybutanoate.

Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.

Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.

Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).

Compositions and methods having antiviral properties, such as for the prevention, treatment or providing nutritional or other benefits in animals, including humans and livestock, having or at risk of viral-mediated disorders. Methods may provide nutritional benefits in a human or animal subject, comprising administering a composition of the present invention. Compositions may comprise monoglycerides and essential oils, including compositions comprising two or more of the following components: a monoglyceride, a curcuminoid, thymoquinone, thymol, carvacrol, and p-cymene. Such viral mediated disorders may be associated with viruses of the family Coronaviridae (e.g., MERS-CoV, SARS-CoV, SARS-CoV-2), viruses of the family Orthomyxoviridae (e.g., Influenza A, Influenza B), Porcine Epidemic Diarrhea Virus, Transmissible Gastroenteritis, Porcine Respiratory Reproductive Syndrome, African Swine Fever Virus, Foot-and-Mouth Virus, Seneca Valley Virus, Influenza A, Avian Influenza H5N1, Rotavirus A, Rotavirus B, Rotavirus C, or Rotavirus D.